



---

# 1<sup>st</sup> European Ovarian Cancer Research Symposium 2026

*Improving ovarian cancer outcomes: harnessing tumor-host interactions*

**CCBIO Satellite Symposium**

May 10-11, 2026 (Bergen - Norway)

## Scientific Program

---

### Day 1: Sunday May 10, 2026

09:00-10.45 REGISTRATION

10.45-11.00 Welcome and opening - Line Bjørge co-Director CCBIO

Session 1: Early detection/tumor initiation – Chairs: Wennerberg & Hedenfalk

11:00-11.30: Invited talk Usha Menon (London)

*Early Detection and Interception of Ovarian Cancer- Challenges and Opportunities*

11.30-12.00: Invited talk Ronny Drapkin (Philadelphia)

*A Pre-Cancer Atlas of Ovarian Cancer Initiation in the Fallopian Tube*

- Dentist Olaf Aase and wife memorial lecture

12.00-12.15: Selected short talk Tanjina Kader (Boston)

*Spatial integration of protein and chromosomal states reveals early aneuploidy and genotype-associated immune neighborhoods in serous ovarian cancer evolution*

12.15-12.30: Selected short talk Michail Sideris (London)

*Reconstruction of epithelial transcriptional trajectories reveals heterogeneous progression and early therapy-resistance programs in high-grade serous carcinoma precursors*

12:30-14:00 LUNCH AND POSTER SESSION I

**Session 2: Ethnic and histological diversity – Chairs: Drapkin & Zahl Eriksson**

- 14:00-14.30: Invited talk Charlie Gourley** (Edinburgh)  
*Rare Ovarian Cancer Subtypes: What We Do and Don't Know About Their Biology and Its Relevance for Novel Therapeutic Strategies'*
- 14.30-15.00: Invited talk Susana Banerjee** (London)  
*Clinical trials in Rare Ovarian Cancers: Challenges and Progress*
- 15.00-15.15: Selected short talk Sofia Westbom Fremer** (Lund)  
*Altered Immune Landscapes in Ovarian Endometriosis Prior to Ovarian Cancer Onset*
- 15.15-15.30: Selected short talk Michael Anglesio** (Vancouver)  
*Integrating Molecular Subtypes and Hormone Receptors Improves Outcome Prediction: a Multi-National Endometrioid Ovarian Cancer Collaborative (MECC) study*

15:30-16:00 COFFEE BREAK

**Session 3: Biomarkers and precision oncology – Chairs: Jacobs & Färkkilä**

- 16:00-16.30: Invited talk Sampsa Hautaniemi** (Helsinki)  
*Mechanisms and Vulnerabilities of Chemotherapy Resistant HGSC*
- 16.30-17.00: Invited talk Olivia Le Saux** (Lyon)  
*Predictive Biomarkers of Response and Resistance to Immune Checkpoint Blockade*
- 17.00-17.15: Selected short talk Ruth Perets** (Haifa)  
*Utilizing the population shift hypothesis to inhibit PAX8 as a novel ovarian cancer therapy*
- 17.15 -17.30: Selected short talk Ada Junquera** (Helsinki)  
*Single-cell multiomics profiling of HGSC reveals spatially segregated trajectories of 'subsister cells' associated with clinical outcomes*

19.00 APERITIF

20.00 DINNER

**Day 2: Monday May 11, 2026**

**Session 4: Preclinical modelling – Chairs: Drapkin & Senkowski**

- 09:00-09.30: Invited talk Frances Balkwill** (London)  
*Multi-cellular in vitro Models for Pre-Clinical Modelling*
- 09:30-10.00: Invited talk Krister Wennerberg** (Copenhagen)  
*Exploring and Targeting Drug Resistance Using Ovarian Cancer Organoid Models*
- 10.00-10.15: Short selected talk Katrin Kleinmanns** (Bergen)  
*Single-cell transcriptomic signatures identify drug combinations to address platinum resistance in ovarian cancer*
- 10.15.10.30: Short selected talk Jordi Gonzalez-Molina** (Stockholm)  
*Modelling the complex biophysical microenvironment in ovarian cancer*

10:30-11:00 COFFEE BREAK

**Session 5 Immunology and spatial biology - Chairs: Bjørge & Wennerberg**

- 11:00-11.30: Invited talk Denarda Dangaj** (Lausanne)  
*From Immune Presence to Immune Function: Functional and Spatial Biomarkers in Ovarian Cancer Immuno-Oncology*

- 11.30-12.00: Invited talk Anniina Färkkilä (Helsinki)**  
*Single-Cell Spatial Tumor Ecosystems in HGSC: Clinical Impact and Opportunities for Immunotherapy*
- 12.00-12.15: Short selected talk Shimrit Mayer (Cambridge)**  
*A multicellular spatial atlas stratifies epithelial ovarian cancer*
- 12.15- 12.30: Short selected talk Nathaniel E B Saidu (Oslo)**  
*Targeting Prostaglandin E2 Signaling for Restoring T Cell Function in Metastatic Ovarian Cancer*
- 12:30-14:00 LUNCH BREAK AND POSTER SESSION II

**Session 6 Emerging cell types and targets – Chairs: Färkkilä & Balkwill**

- 14:00-14.30: Invited talk Hanna Dahlstrand (Stockholm)**  
*Cancer-Associated Fibroblasts in Ovarian Cancer: Biological Impact and Clinical Relevance*
- 14.30-15.00: Invited talk Frederik Marmé (Mannheim)**  
*Antibody-Drug Conjugates in Ovarian Cancer*
- 15.00-15.15: Short selected talk Ricardo Coelho (Basel)**  
*Chemotherapy primes tumor-associated macrophages to enable caspase-8 dependent apoptosis triggered by birinapant in ovarian cancer cells*
- 15.15-15.30: Short selected talk Shriya Varghese (London)**  
*Profiling Cancer-Associated Fibroblasts in Advanced High-Grade Serous Ovarian Cancer Reveals Intra- and Inter-Patient Heterogeneity*
- 16.30- 16:45 **Closing remarks - Anniina Färkkilä**

---

**Satellite Symposium to the [14<sup>th</sup> CC BIO Annual Symposium 2026](#)**



Centre for  
Cancer Biomarkers